# Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

> **NCT00296387** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1160 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00296387
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 1160 (ESTIMATED)
- **Last updated:** 2007-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00296387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00296387, "Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00296387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*